Shp2: Indoline Scaffold Protein Tyrosine Phosphatase Inhibitors

Shp2 is a protein tyrosine phosphatase (PTPase) that mediates growth factor and cytokine signaling. Aberrant Shp2 expression is associated with several types of leukemias and developmental disorders.

COMMERCIAL OPPORTUNITY

  • SPI-112Me is a novel small molecule that inhibits a specific target. It has drug-like properties of size, solubility and cell permeability.
  • Targeted inhibitors of Shp2 represent a new class of drugs that may have uses in treating several diseases including acute myelogenous leukemia (AML).
  • Current treatment for AML relies on cytotoxics and antimetabolites, and/or stem cell transplantation. Most patients receive induction chemotherapy with cytarabine and an anthracycline to attempt remission, followed by consolidation therapy that includes more courses of chemotherapy. Many AML patients are elderly and not candidates for intense chemotherapy or cell transplantation.
  • Targeted therapies may be a new mode for improving outcomes of this disease, which has relapse rates from 33 to 78%, depending on the type of AML. Elderly patients in particular may benefit from a Shp2-targeted therapy.

TECHNOLOGY

  • Shp2 is a protein tyrosine phosphatase (PTPase) that mediates growth factor and cytokine signaling. It is also involved in cell transformation by oncogenic growth factor receptor kinases and by the oncogenic bacterium H. pylori. Mutations of Shp2 are associated with several types of leukemias as well as the developmental disorder Noonan Syndrome.
  • Because aberrant Shp2 activation may have a role in cell transformation, Shp2 PTPase is a target for developing oncology therapeutics.
  • Scientists at Moffitt Cancer Center have discovered a novel drug-like compound that selectively inhibits the Shp2 PTPase. This compound may be a lead drug for treating a variety of Shp2-associated cancers.

PUBLICATION/PATENT

  • L. Chen et al. (2006) Mol. Pharmacol. 70(2):562-570
  • H. Lawrence et al. (2008) J. Med Chem. 51(16):4948-56
  • US patent application 11/733,023 filed April 9, 2007
  • US patent application 13/055,113 filed July 21, 2009
  • PCT application PCT/US09/042305 filed April 30, 2009
  • PCT application PCT/US10/031506 filed April 16, 2010
  • Provisional application filed March 30, 2011

Contact

Haskell Adler PhD MBA CLP
Senior Licensing Manager
Registered Patent Agent
Haskell.Adler@Moffitt.org
(813) 745-6596

06A038